Every material Form 8-K ORASURE TECHNOLOGIES INC has filed with the SEC since June 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
OraSure reported second quarter 2026 revenue of $30.6 million, down 2% from a year earlier but up about 10% from the first quarter, and GAAP net income of $6.2 million compared with a $19.7 million loss a year earlier. The swing was driven mainly by a $22.6 million reduction in its contingent consideration liability, while non-GAAP net loss was $13.8 million. The company guided third quarter 2026 revenue to $29.5 million to $32.5 million.
Q2 2026 net revenues $30.6 million, down 2% year over year and up 10% sequentially; core revenues flat year over year at $30.6 million.
GAAP net income $6.2 million (diluted EPS $0.09) versus a GAAP net loss of $19.7 million in Q2 2025; non-GAAP net loss $13.8 million.
Recorded a $22.6 million reduction in contingent consideration liability tied to an updated submission plan for the InteliQuick CT/NG test.
Q3 2026 revenue guidance of $29.5 million to $32.5 million; cash and equivalents $161 million at June 30, 2026.
OraSure Technologies said the FDA cleared its Colli-Pee Dx Urine Collection Kit, made by subsidiary DNA Genotek, for use with Roche Molecular Systems tests for four sexually transmitted infections run on Roche's cobas 5800, 6800 and 8800 systems. The kit supports at-home self-collection of first-void urine for male and female patients. The filing does not provide financial figures or a sales outlook tied to the clearance.
FDA clearance announced June 11, 2026, for the Colli-Pee Dx Urine Collection Kit from DNA Genotek Inc.
Cleared for use with Roche tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium
Compatible with Roche cobas 5800, 6800 and 8800 molecular diagnostic systems
Kit supports at-home self-collection of first-void urine for male and female patients
At its June 3, 2026 annual meeting, OraSure stockholders approved an amendment and restatement of the Stock Award Plan that adds 5,000,000 shares for grant, and a charter amendment to declassify the board over three years beginning at the fiscal 2027 annual meeting. The charter amendment became effective upon its filing with the Delaware Secretary of State on June 3, 2026. For shareholders, the plan increase expands the share pool available for equity awards, and directors will move to annual elections over the phase-in period.
Stock Award Plan amendment adds 5,000,000 shares for grant; 57,055,163 votes for and 4,796,974 against
Board declassification approved with 49,125,748 votes for and 2,223,960 against; directors move to one-year terms from the fiscal 2027 annual meeting
Annual meeting held virtually; record date April 10, 2026 with 71,965,612 outstanding common shares
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ORASURE TECHNOLOGIES INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →